Hjem › Småcellet lungekreft › Washington
Kliniske studier for Småcellet lungekreft i Washington
13 studier for Småcellet lungekreft søker deltakere på steder i Washington.
Byer i Washington
Offisiell studietekst (engelsk)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Washington, Fred Hutchinson Cancer Center, Seattle
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT04585750Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Northwest Medical Specialties, Tacoma
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 24. sep. 2026 · NCT06047379Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
- Fred Hutchinson Cancer Research Center, Seattle
RekruttererFase 1
Alder 18 til 100 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07006727Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- University of Washington Fred Hutchinson, Seattle
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 21. sep. 2026 · NCT05983432A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
- Fred Hutchinson Cancer Center, Seattle
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. sep. 2026 · NCT07564401A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Swedish Cancer Institute - Edmonds, Edmonds
- Swedish Medical Center, Seattle
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 11. sep. 2026 · NCT06646276AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Seattle
RekruttererFase 1/2
Alder 18 til 75 · Alle kjønn · Oppdatert 4. sep. 2026 · NCT07038343Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Fred Hutch Cancer Research, Seattle
RekruttererFase 1/2
Alder 18 til 100 · Alle kjønn · Oppdatert 27. aug. 2026 · NCT06726148A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
- Northwest Cancer Specialists, Vancouver
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT06095505A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- Fred Hutch Cancer Center, Seattle
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 15. jul. 2026 · NCT05652686A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
- Swedish Cancer Institute, Seattle
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 9. jul. 2026 · NCT07174583Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
- Swedish Cancer Institute, Seattle
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 26. jun. 2026 · NCT06598306A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 105, Spokane
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 21. nov. 2025 · NCT05914116Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.